Development of a reliable assay to measure glypican-1 in plasma and serum reveals circulating glypican-1 as a novel prostate cancer biomarker

• Published in: Oncotarget Vol. 9; no. 32; pp. 22359 - 22367
• Main Authors: Levin, Rachel A, Lund, Maria E, Truong, Quach, Wu, Angela, Shore, Neal D, Saltzstein, Daniel R, Concepcion, Raoul S, Paivanas, Thomas A, van Breda, Arletta, Beebe-Dimmer, Jennifer, Ruterbusch, Julie J, Wissmueller, Sandra, Campbell, Douglas H, Walsh, Bradley J
• Format: Journal Article
• Language: English
• Published: United States Impact Journals LLC 27.04.2018
• Subjects: Research Paper; 3G5; prostate cancer; biomarker; glypican-1; MIL-38

Prostate cancer is responsible for hundreds of thousands of annual deaths worldwide. The current gold standard in early detection of prostate cancer, the prostate specific antigen test, boasts a high sensitivity but low specificity, resulting in many unnecessary prostate biopsies. Thus, emphasis has...